HRP20040403A2 - Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same - Google Patents

Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same Download PDF

Info

Publication number
HRP20040403A2
HRP20040403A2 HR20040403A HRP20040403A HRP20040403A2 HR P20040403 A2 HRP20040403 A2 HR P20040403A2 HR 20040403 A HR20040403 A HR 20040403A HR P20040403 A HRP20040403 A HR P20040403A HR P20040403 A2 HRP20040403 A2 HR P20040403A2
Authority
HR
Croatia
Prior art keywords
temperature
rimonabant
methylcyclohexane
medium
mixture
Prior art date
Application number
HR20040403A
Other languages
English (en)
Croatian (hr)
Inventor
Alain Alcade
Gilles Anne-Archard
Corinne Gavory
Olivier Monnier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HRP20040403A2 publication Critical patent/HRP20040403A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20040403A 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same HRP20040403A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/003765 WO2003040105A1 (fr) 2001-11-08 2002-11-04 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
HRP20040403A2 true HRP20040403A2 (en) 2004-08-31

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040403A HRP20040403A2 (en) 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same

Country Status (33)

Country Link
US (2) US20050043356A1 (sr)
EP (1) EP1446384A1 (sr)
JP (2) JP4181994B2 (sr)
KR (2) KR20050043774A (sr)
CN (1) CN100412063C (sr)
AP (1) AP1830A (sr)
AR (1) AR037253A1 (sr)
AU (1) AU2002350869B2 (sr)
BR (1) BR0213931A (sr)
CA (1) CA2464145A1 (sr)
CO (1) CO5580827A2 (sr)
CR (1) CR7333A (sr)
EA (1) EA006771B1 (sr)
EC (1) ECSP045088A (sr)
FR (1) FR2831883B1 (sr)
GE (1) GEP20063894B (sr)
HR (1) HRP20040403A2 (sr)
HU (1) HUP0402043A3 (sr)
IL (2) IL161533A0 (sr)
IS (1) IS7226A (sr)
MA (1) MA27080A1 (sr)
ME (1) MEP21908A (sr)
MX (1) MXPA04004394A (sr)
NO (1) NO326648B1 (sr)
NZ (1) NZ532369A (sr)
OA (1) OA12721A (sr)
PL (1) PL369372A1 (sr)
RS (1) RS36904A (sr)
TN (1) TNSN04079A1 (sr)
TW (1) TW200302824A (sr)
UA (1) UA76776C2 (sr)
WO (1) WO2003040105A1 (sr)
ZA (1) ZA200402999B (sr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
EP1910290A2 (en) 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
AR062593A1 (es) * 2006-08-29 2008-11-19 Medichem Sa 1-{[5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metil-1h-pirazol-3-il]carbonil}-piperidina y proceso para preparar dicho compuesto; proceso para analizar la pureza de rimonabant,proceso para preparar rimonabant,rimonabant que se obtiene mediante dicho proceso y formulaciones.
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them
EP2121659B1 (en) * 2006-12-18 2013-05-15 7TM Pharma A/S Modulators of cb1 receptors
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
EP1944297A1 (en) * 2007-01-09 2008-07-16 Miklós Vértessy Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
EP1953144A1 (en) 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009153804A1 (en) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Process for preparing form i of rimonabant
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
JP7704681B2 (ja) * 2019-10-16 2025-07-08 大塚製薬株式会社 センタナファジンの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US7109245B2 (en) * 2001-08-15 2006-09-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
HUP0402043A2 (hu) 2005-01-28
EA200400491A1 (ru) 2004-12-30
MEP21908A (en) 2010-06-10
CR7333A (es) 2008-09-23
JP4931874B2 (ja) 2012-05-16
HUP0402043A3 (en) 2009-07-28
JP2005508383A (ja) 2005-03-31
IL161533A0 (en) 2004-09-27
US20100190827A1 (en) 2010-07-29
PL369372A1 (en) 2005-04-18
NO326648B1 (no) 2009-01-26
FR2831883B1 (fr) 2004-07-23
RS36904A (sr) 2006-10-27
AR037253A1 (es) 2004-11-03
JP4181994B2 (ja) 2008-11-19
EA006771B1 (ru) 2006-04-28
WO2003040105A1 (fr) 2003-05-15
GEP20063894B (en) 2006-08-10
AP1830A (en) 2008-02-22
FR2831883A1 (fr) 2003-05-09
BR0213931A (pt) 2004-09-08
TNSN04079A1 (fr) 2006-06-01
KR20090089485A (ko) 2009-08-21
NZ532369A (en) 2005-10-28
IL161533A (en) 2010-05-31
CN100412063C (zh) 2008-08-20
ZA200402999B (en) 2005-04-20
EP1446384A1 (fr) 2004-08-18
JP2009035547A (ja) 2009-02-19
UA76776C2 (uk) 2006-09-15
KR20050043774A (ko) 2005-05-11
ECSP045088A (es) 2004-06-28
MXPA04004394A (es) 2004-08-11
AP2004003024A0 (en) 2004-06-30
IS7226A (is) 2004-04-19
CO5580827A2 (es) 2005-11-30
OA12721A (fr) 2006-06-27
CA2464145A1 (en) 2003-05-15
TW200302824A (en) 2003-08-16
AU2002350869B2 (en) 2007-07-26
US20050043356A1 (en) 2005-02-24
CN1582278A (zh) 2005-02-16
NO20041879L (no) 2004-06-08
MA27080A1 (fr) 2004-12-20
NO20041879D0 (no) 2004-05-07

Similar Documents

Publication Publication Date Title
HRP20040403A2 (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
TWI846166B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
HU213211B (en) Process for producing new physical modification of n-/4-(5-(cyclopentyl oxycarbonyl)amino-1-methylindol-3-yl-methyl)-3-methoxybenzoyl/-2-methyl benzenesulphonamide and pharmaceutical compositions comprising the same
KR20010033141A (ko) 약제로서의5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온 말레산 염 수화물
JPH11502230A (ja) インダゾールカルボキサミド類
MX2012000749A (es) Bencensulfonato de 2-[[[2-[(hidroxiacetil) amino]-4-piridinil]meti l] tio]-n-[4-(trifluorometox)fenil]-3-piridincarboxamida, cristal del mismo, cristal polimorfo de este y metodos para la produccion de estos.
JP2000516258A (ja) 薬剤の結晶変形
JP2018172403A (ja) 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
KR20020032627A (ko) 다형태 염
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
WO2010111951A1 (zh) 普拉格雷氢溴酸盐的晶体
KR101476508B1 (ko) (S)-베포타스틴 p-톨루엔술폰산염의 신규 결정형 및 이의 제조방법
HUP0700046A2 (en) Crytalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist, manufacture use thereof and pharmaceutical composition containing thereof
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
CA2595675A1 (en) Form iv crystalline celecoxib
HU210879A9 (en) Pharmaceutical agents
BRPI0707997A2 (pt) forma cristalizada i de besipiridina.hcl, processo para sua obtenção, uso desta e composição terapêutica
JP2001518088A (ja) 抗不整脈薬として有用なニトロベンズアミド
JP2007525502A (ja) コナゾール類の新規な結晶形態並びにそれらの製造および使用方法
WO2005077359A1 (ja) インドリン化合物を含有する安定化された医薬組成物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

ODRP Renewal fee for the maintenance of a patent

Payment date: 20091102

Year of fee payment: 8

OBST Application withdrawn